Last reviewed · How we verify
Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| infliximab+azathioprine | infliximab+azathioprine | marketed | TNF-α inhibitor + immunosuppressant combination | TNF-α receptor (infliximab); purine metabolism (azathioprine) | Immunology / Gastroenterology | |
| methylprednisolone or budesonide | methylprednisolone or budesonide | marketed | Corticosteroid | Glucocorticoid receptor | Immunology / Gastroenterology |
Therapeutic area mix
- Immunology / Gastroenterology · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- AIDS Malignancy Consortium · 1 shared drug class
- ANI Pharmaceuticals · 1 shared drug class
- AbbVie · 1 shared drug class
- Acrotech Biopharma Inc. · 1 shared drug class
- Allergan · 1 shared drug class
- Aramis Biosciences, Inc. · 1 shared drug class
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW:
- Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW pipeline updates — RSS
- Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW pipeline updates — Atom
- Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/belgian-inflammatory-bowel-disease-research-and-development-bird-vzw. Accessed 2026-05-17.